MetaVia is trading at $1.52, up +10.14%, with no confirmed company-specific catalyst for the October 26 pre-market move.

  • No new company-specific catalyst explaining the October 26 pre-market move was identified.
  • MetaVia’s investor-relations page lists its October 13 chief medical officer appointment as its latest press release; it predates the move and does not establish a direct cause.
  • The S&P 500 and Dow were slightly higher, while the Nasdaq was slightly lower, so the mixed market picture does not clearly explain the rise.